Drug Profile
Research programme: bromodomain and extraterminal domain protein inhibitors - Checkpoint Therapeutics
Alternative Names: BET inhibitors; BRD4 InhibitorsLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Jubilant Biosys
- Developer Checkpoint Therapeutics; Jubilant Biosys; TG Therapeutics Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action BRD4 protein inhibitors; Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Mar 2022 Preclinical development is still ongoing in Cancer in USA (Jubilant Therapeutics pipeline, March 2022)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in USA